Biologics Fill Finish Services Market Industry Trends and Global Forecasts to 2035, by Type of Primary Packaging Container, Type of Biologic Manufactured, Scale of Operation, Therapeutic Area, End-users, Type of Player and and Key Geographical Regions

The global biologics fill finish manufacturing market is estimated to grow from USD 5.3 billion in 2025, to USD 11.6 billion by 2035, at a CAGR of 7.4% during the forecast period, till 2035.

Biologics Fill Finish Services Market: Growth and Trends

Biopharmaceuticals, commonly referred to as biologics, are a class of therapeutic products that are either derived from living organisms or semi-synthesized from biological sources. Unlike traditional small molecules, these macromolecules are complex and are developed to target specific protein receptors in the body. It is worth mentioning that, over the years, these therapies have gained immense popularity owing to their favorable therapeutic outcomes demonstrated across various therapeutic areas, such as oncological disorders, infectious diseases and neurovascular disorders. Further, the evolution of drug development process has led to technical advancements that have further streamlined the entire process of manufacturing these complex biologics. However, it is worth noting that the biopharmaceutical industry has dealt with several challenges, in terms of inadequate capital investments, sterility issues, and stringent quality standards imposed by different regulatory authorities globally. As a result, outsourcing of manufacturing and fill / finish operations for biologics has emerged as a suitable option to meet the evolving demand of the industry. Driven by the growing demand for biologics and technological advancements (such as use of automation and robotics) in fill finish operations, the biologics fill finish manufacturing market is anticipated to witness substantial market growth, during the forecast period.

Biologics Fill Finish Services Market: Key Insights

The report delves into the current state of the biologics fill finish services market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

Presently, 240+ service providers are engaged in offering fill / finish services for various biologic molecules; close to 35% of these companies are headquartered in the US.

80% of the service providers operate at all scales of operation to cater to the diverse fill / finish requirements of their clients; notably, vials have emerged as the most adopted primary packaging container format.
In pursuit of building a competitive edge, stakeholders are actively upgrading their existing capabilities and enhancing their respective service offerings to comply with the evolving industry benchmarks.
Over the past few years, the field has witnessed a notable increase in expansion and partnership activity for biologics fill / finish capabilities.
The global, installed biologics fill / finish capacity is spread across various geographies; interestingly, more than 90% of the total capacity is installed at the facilities owned by large and very large players.
Given the growing pipeline of biologic drug products, the demand for fill-finish services has upsurged; by 2035, it is anticipated to reach over 28.5 million liters, across clinical and commercial scales of operation.
With the rapid increase in the demand for biologics for the treatment of chronic conditions, the BFF market is poised to grow at a CAGR of 7.4%, till 2035; the market in Asia-Pacific is likely to grow at a faster pace.

Close to 30% of the market is expected to be captured by revenues generated from fill / finish services of biologics for oncological disorders; vials are expected to capture majority share (over 65%) of the market by 2035.

Report Segmentation

Type of Primary Packaging Container

Ampoules
Cartridges
Syringes
Vials

Type of Biologic Manufactured

Antibodies
Cell Therapies
Gene Therapies
Oligonucleotides
Recombinant Proteins
Vaccines
Other Biologics

Scale of Operation

Preclinical / Clinical
Commercial

Therapeutic Area

Autoimmune Disorders
Cardiovascular Disorders
Infectious Diseases
Metabolic Disorders
Oncological Disorders
Other Disorders

End Users

Pharmaceutical / Biopharmaceutical Companies
Contract Manufacturing Organizations / Others

Type of Player

Industry
Non-Industry

Company Size

Small
Mid-sized
Large

Key Geographical Regions

North America (US, Canada and Mexico)
Europe (Austria, France, Germany, Italy, Spain, Switzerland, UK and Rest of Europe)
Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
Rest of the World (Argentina, Brazil, Iran, Israel and Other Countries)

Biologics Fill Finish Services Market: Key Segments

Currently, Vials Occupy the Largest Share of the Biologics Fill Finish Services Market

Based on the type of primary packaging container, the market is segmented into ampoules, cartridges, syringes and vials. At present, the vials segment holds the maximum share of the biologics fill finish services market and this trend is likely to remain the same in the short-mid term. Vials offer various benefits, such as the ability to pre-sterilize the containers using various terminal sterilization techniques, ease of filling and minimal risk of breakage during handling, and transportation. It is worth highlighting that syringes segment is likely to grow at a relatively higher CAGR during the forecast period.

Antibodies Segment is Likely to Dominate the Biologics Fill Finish Services Market During the Forecast Period

Based on the type of biologic manufactured, the market is segmented into antibodies, cell therapies, gene therapies, oligonucleotides, recombinant proteins, vaccines and other biologics. Given that monoclonal antibodies have high specificity and low toxicity, these molecules are widely adopted for various applications leading to the highest share in the biologics fill finish manufacturing market. This trend is unlikely to change in the near future.

Currently, Commercial Scale Occupies the Largest Share of the Biologics Fill Finish Services Market

Based on the scale of operation, the market is segmented into preclinical / clinical and commercial scale. At present, the commercial scale holds the maximum share of the biologics fill finish services market. This trend is likely to remain the same in the forthcoming years.

Oncological Disorders Segment Accounts for the Largest Share of the Biologics Fill Finish Services Market

Based on the therapeutic area, the market is segmented into autoimmune disorders, cardiovascular disorders, infectious diseases, metabolic disorders, oncological disorders and other disorders. While oncological disorders account for a relatively higher market share, it is worth highlighting that autoimmune disorders segment is expected to witness substantial market growth in the coming years.

Small Companies Offering Biologics Fill Finish Services are the Fastest Growing Segment of the Biologics Fill Finish Services Market During the Forecast Period

Based on the company size, the market is segmented into small companies, mid-sized companies, and large companies. It is worth highlighting that, at present, large companies hold a larger share in the biologics fill finish services market. This trend is likely to remain the same in the coming decade.

Pharmaceutical / Biopharmaceutical Companies are Likely to Dominate the Biologics Fill Finish Services Market During the Forecast Period

Based on the end-users, the market is segmented into pharmaceutical / biopharmaceutical companies and contract manufacturing organizations / others. It is worth highlighting that the majority of the current biologics fill finish services market is captured by pharmaceutical / biopharmaceutical companies. This trend is likely to remain the same in the coming decade.

Industry Players are Likely to Dominate the Biologics Fill Finish Services Market During the Forecast Period

Based on the type of player, the market is segmented into industry players and non-industry players. It is worth highlighting that majority of the current biologics fill finish services market is captured by industry players. This trend is likely to remain the same in the coming decade.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. Majority share is expected to be captured by drug developers based in Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Biologics Fill Finish Manufacturing Market Profiled in the Report Include:

AbbVie Contract Manufacturing
Asymchem
Boehringer Ingelheim BioXcellence
Catalent Biologics
Charles River
Evonik
Fareva
Fresenius Kabi
GSK
Hetero
Lonza
Patheon Pharma Services
Pierre Fabre
Recipharm
Sandoz
Syngene
WACKER
WuXi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Former Chief Commercial Officer, IDT Biologika
Vice President of Business Development, Alcami
Vice President, Syngene
Former-Vice President of Business Development and Marketing, Cytovance Biologics
Head of Business Development, oncomed manufacturing
Business Development Manager, Eurofins BioPharma Product Testing Netherlands
Former -Technology Watch Manager, Yposkesi
Former Global Business Development Manager, HALIX
Business Development Specialist, Mabion

Biologics Fill Finish Manufacturing Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biologics fill finish manufacturing market, focusing on key market segments, including [A] type of primary packaging container, [B] type of biologic manufactured, [C] scale of operation, [D] therapeutic area, [E] end-users, [F] type of player, [G] company size and [H] key geographical regions.
Market Landscape: A comprehensive evaluation of companies involved in the biologics fill finish manufacturing market, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] location of fill finish facilities, [E] scale of operation, [F] type of biologic manufactured, [G] type of dosage form, [H] type of primary packaging container used and [I] additional services offered.
Company Profiles: In-depth profiles of key industry players offering biologics fill finish services, focusing on [A] company overviews, [B] financial information (if available), [C] fill / finish service portfolio, [D] recent developments and [E] an informed future outlook.
Company Competitiveness Analysis: A comprehensive competitive analysis of biologics fill finish manufacturing service providers, examining factors such as [A] supplier strength, [B] portfolio strength and [C] service strength.
Partnerships and Collaborations: An analysis of partnerships established in this sector, based on several parameters, such as [A] year of partnership, [B] type of partnership (including service agreement, service alliance, product integration agreement and joint venture and acquisition), [C] scale of operation, [D] type of service offered, [E] type of process involved, [F] type of biologic involved, [G] location of headquarters or location of facility and [H] most active players (in terms of number of partnerships).
Recent Expansion Initiatives: An examination of the different expansion efforts made by contract manufacturing organizations to enhance biologics fill finish capabilities. This analysis considers various factors, including the [A] year of expansion, [B] type of expansion, [C] type of primary packaging container used, [D] type of service offered, [E] type of biologic involved, [F] scale of operation, [G] most active players (in terms of number of expansion initiatives) and [H] expansion details.
Capacity Analysis: Estimation of global biologics fill finish capacity, derived from data provided by various industry stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size (small, mid-sized, and large and very large firms) and [B] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).
Demand Analysis: Informed estimates of the annual demand for biologics fill-finish manufacturing based on several relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength of the aforementioned products.
Key Performance Indicators: An analysis highlighting the key performance indicators to evaluate service providers engaged in the biologics fill finish domain, based on information gathered via secondary research (for top-ten biopharmaceutical players) and primary research.
Capability Assessment: A comprehensive regional capability assessment framework that evaluates key geographies by various parameters, including [A] number of biologics fill finish service providers, [B] number of biologics fill finish facilities, [C] scale of operation, [D] installed biologic fill/finish capacity and [E] annual demand in that particular geographical region.
Case Study 1: A case study focused on use of robotic systems in fill/finish operations. It provides a list of equipment used by the service providers (wherever specified) for fill finish operations, highlighting the purpose of robotics in various manufacturing operations. It also includes a list of companies providing robots for use in manufacturing processes carried in the pharmaceutical industry.
Case Study 2: A case study on the use of ready to use packaging components in the aseptic fill finish operations. It also provides a list of suppliers providing ready-to-use components.
Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

Key Questions Answered in this Report

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What is the current annual demand for biologics?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

SECTION I: REPORT OVERVIEW

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Value and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross-Border Dynamics
4.3. Conclusion

SECTION II: QUALITATIVE INSIGHTS5. EXECUTIVE SUMMARY

6. INTRODUCTION

6.1. Chapter Overview
6.2. Introduction to Biologics
6.3. Need for Outsourcing Biologics-related Operations
6.4. Role of Contract Manufacturers in the Biopharmaceutical Industry
6.5. Commonly Outsourced Operations in the Biopharmaceutical Industry
6.5.1. Biologics Fill / Finish Operations
6.6. Key Considerations while Selecting a Fill / Finish Service Provider
6.7. Advantages of Outsourcing Fill / Finish Operations
6.8. Risks and Challenges associated with Outsourcing Fill / Finish Operations
6.9. Conclusion

SECTION III: MARKET OVERVIEW

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Biologics Fill / Finish Service Providers: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Location of Fill / Finish Facilities
7.2.5. Analysis by Scale of Operation
7.2.6. Analysis by Type of Biologic Manufactured
7.2.7. Analysis by Presence of Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability
7.2.8. Analysis by Type of Dosage Form
7.2.9. Analysis by Type of Primary Packaging Container Used
7.2.10. Analysis by Additional Services Offered

8. COMPANY COMPETITIVENESS ANALYSIS

8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Methodology
8.4. Overview of Peer Groups
8.5. Biologics Fill / Finish Service Providers: Company Competitiveness Analysis
8.5.1. Biologics Fill / Finish Service Providers based in North America (Peer Group I)
8.5.2. Biologics Fill / Finish Service Providers based in Europe (Peer Group II)
8.5.3. Biologics Fill / Finish Service Providers based in Asia-Pacific and Rest of the World (Peer Group III)

SECTION IV: COMPANY PROFILES

9. COMPANY PROFILES: BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN NORTH AMERICA

9.1. Chapter Overview
9.2. AbbVie Contract Manufacturing
9.2.1. Company Overview
9.2.2. Financial Information
9.2.3. Biologics Fill / Finish Service Portfolio
9.2.4. Recent Developments and Future Outlook
9.3. Alcami
9.4. Catalent Biologics
9.5. Charles River
9.6. Curia
9.7. Grand River Aseptic Manufacturing
9.8. Lifecore Biomedical
9.9. Novocol Pharma
9.10. Patheon pharma services
9.11. Pharmaceutics International (Pii)

10. COMPANY PROFILES: BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN EUROPE

10.1. Chapter Overview
10.2. Boehringer Ingelheim BioXcellence
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Biologics Fill / Finish Service Portfolio
10.2.4. Recent Developments and Future Outlook
10.3. Cenexi
10.4. CordenPharma
10.5. Element Materials Technology
10.6. Evonik
10.7. Fareva
10.8. Fresenius Kabi
10.9. GSK
10.10. Lonza
10.11. Northway Biotechpharma
10.12. Rechon Life Science
10.13. Recipharm
10.14. WACKER

11. COMPANY PROFILES: BIOLOGICS FILL / FINISH SERVICE PROVIDERS IN ASIA-PACIFIC

11.1. Chapter Overview
11.2. Asymchem
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Biologics Fill / Finish Service Portfolio
11.2.4. Recent Developments and Future Outlook
11.3. Bushu Pharmaceuticals
11.4. Hetero
11.5. Syngene
11.6. WuXi Biologics

SECTION V: MARKET TRENDS

12. PARTNERSHIPS AND COLLABORATIONS

12.1. Chapter Overview
12.2. Partnership Models
12.3. Biologics Fill / Finish Service Providers: Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Year and Type of Partnership
12.3.4. Analysis by Scale of Operation
12.3.5. Analysis by Type of Partner Company
12.3.6. Most Active Players: Analysis by Number of Partnerships
12.3.7. Analysis by Geography
12.3.7.1. Local and International Agreements
12.3.7.2. Intracontinental and Intercontinental Agreements

13. RECENT EXPANSIONS

13.1. Chapter Overview
13.2. Expansion Models
13.3. Biologics Fill / Finish Service Providers: Recent Expansions
13.3.1. Analysis by Year of Expansion
13.3.2. Analysis by Type of Expansion
13.3.3. Analysis by Year and Type of Expansion
13.3.4. Analysis by Location of Expanded Facility
13.3.5. Analysis by Type of Expansion and Location of Expanded Facility
13.3.6. Analysis by Area of Expanded Facility
13.3.7. Analysis by Scale of Operation
13.3.8. Analysis by Type of Primary Packaging Container Used
13.3.9. Analysis by Type of Expansion and Type of Primary Packaging Container Used
13.3.10. Analysis by Amount Invested
13.3.11. Most Active Players: Analysis by Number of Expansion Initiatives

14. STRATEGIC OUTSOURCING IN BIOPHARMACEUTICAL FILL / FINISH OPERATIONS: EVALUATING THE CAPABILITY GAPS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Key Insights
14.3.1. Trends Observed across Small Companies
14.3.2. Trends Observed across Mid-sized Companies
14.3.3. Trends Observed across Large Companies
14.3.4. Trends Observed across Very Large Companies
14.4. Conclusion

15. CAPACITY ANALYSIS

15.1. Chapter Overview
15.2. Global Installed Biologics Fill / Finish Capacity for Ampoules (Number of Units / Batch)
15.2.1. Key Assumptions and Methodologies
15.2.2. Analysis by Company Size
15.2.3. Analysis by Geography
15.2.3.1. Analysis of Biologics Fill / Finish Capacity for Ampoules in North America
15.2.3.2. Analysis of Biologics Fill / Finish Capacity for Ampoules in Europe
15.2.3.3. Analysis of Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific
15.2.3.4. Analysis of Biologics Fill / Finish Capacity for Ampoules in Rest of the World
15.3. Global Installed Biologics Fill / Finish Capacity for Cartridges (Number of Units / Batch)
15.3.1. Key Assumptions and Methodologies
15.3.2. Analysis by Company Size
15.3.3. Analysis by Geography
15.3.3.1. Analysis of Biologics Fill / Finish Capacity for Cartridges in North America
15.3.3.2. Analysis of Biologics Fill / Finish Capacity for Cartridges in Europe
15.3.3.3. Analysis of Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific
15.3.3.4. Analysis of Biologics Fill / Finish Capacity for Cartridges in Rest of the World
15.4. Global Installed Biologics Fill / Finish Capacity for Syringes (Number of Units / Batch)
15.4.1. Key Assumptions and Methodologies
15.4.2. Analysis by Company Size
15.4.3. Analysis by Geography
15.4.3.1. Analysis of Biologics Fill / Finish Capacity for Syringes in North America
15.4.3.2. Analysis of Biologics Fill / Finish Capacity for Syringes in Europe
15.4.3.3. Analysis of Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
15.4.3.4. Analysis of Biologics Fill / Finish Capacity for Syringes in Rest of the World
15.5. Global Installed Biologics Fill / Finish Capacity for Vials (Number of Units / Batch)
15.5.1. Key Assumptions and Methodologies
15.5.2. Analysis by Company Size
15.5.3. Analysis by Geography
15.5.3.1. Analysis of Biologics Fill / Finish Capacity for Vials in North America
15.5.3.2. Analysis of Biologics Fill / Finish Capacity for Vials in Europe
15.5.3.3. Analysis of Biologics Fill / Finish Capacity for Vials in Asia-Pacific
15.5.3.4. Analysis of Biologics Fill / Finish Capacity for Vials in Rest of the World
15.6. Concluding Remarks

16. DEMAND ANALYSIS

16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Global Annual Demand for Biologics Fill / Finish Manufacturing (in Million Liters)
16.3.1. Analysis by Scale of Operation
16.3.2. Analysis by Type of Primary Packaging Container Used
16.3.3. Analysis by Geography

17. REGIONAL CAPABILITY ANALYSIS

17.1. Chapter Overview
17.2. Key Assumptions and Parameters
17.3. Biologics Fill / Finish Manufacturing Capabilities in North America
17.4. Biologics Fill / Finish Manufacturing Capabilities in Europe
17.5. Biologics Fill / Finish Manufacturing Capabilities in Asia-Pacific and Rest of the World

SECTION VI: MARKET OPPORTUNITY ANALYSIS

18. MARKET IMPACT ANALYSIS

18.1. Chapter Overview
18.2. Market Drivers
18.3. Market Restraints
18.4. Market Opportunities
18.5. Market Challenges
18.6. Conclusion

19. GLOBAL BIOLOGICS FILL / FINISH MANUFACTURING MARKET

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates, Till 2035
19.3.1. Roots Analysis Perspective on Market Growth
19.3.2. Multivariate Scenario Analysis
19.3.2.1. Conservative Scenario
19.3.2.2. Optimistic Scenario
19.4. Key Market Segmentations

20. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PRIMARY PACKAGING CONTAINER USED

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container Used
20.3.1. Biologics Fill / Finish Manufacturing Market for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.2. Biologics Fill / Finish Manufacturing Market for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.3. Biologics Fill / Finish Manufacturing Market for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.4. Biologics Fill / Finish Manufacturing Market for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.4. Biologics Fill / Finish Manufacturing Market, by Type of Primary Packaging Container Used: Market Dynamics Assessment
20.4.1. Market Movement Analysis
20.4.2. Penetration-Growth (P-G) Matrix

21. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologic Manufactured
21.3.1. Biologics Fill / Finish Manufacturing Market for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.2. Biologics Fill / Finish Manufacturing Market for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.3. Biologics Fill / Finish Manufacturing Market for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.4. Biologics Fill / Finish Manufacturing Market for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.5. Biologics Fill / Finish Manufacturing Market for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.6. Biologics Fill / Finish Manufacturing Market for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.7. Biologics Fill / Finish Manufacturing Market for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)

22. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY SCALE OF OPERATION

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation
22.3.1. Biologics Fill / Finish Manufacturing Market for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2. Biologics Fill / Finish Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)

23. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY THERAPEUTIC AREA

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area
23.3.1. Biologics Fill / Finish Manufacturing Market for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.3.2. Biologics Fill / Finish Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.3.3. Biologics Fill / Finish Manufacturing Market for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.3.4. Biologics Fill / Finish Manufacturing Market for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.3.5. Biologics Fill / Finish Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
23.3.6. Biologics Fill / Finish Manufacturing Market for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)

24. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY END USER

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Biologics Fill / Finish Manufacturing Market: Distribution by End User
24.3.1. Biologics Fill / Finish Manufacturing Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
24.3.2. Biologics Fill / Finish Manufacturing Market for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)

25. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY TYPE OF PLAYER

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player
25.3.1. Biologics Fill / Finish Manufacturing Market for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
25.3.2. Biologics Fill / Finish Manufacturing Market for Non-Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)

26. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY COMPANY SIZE

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Biologics Fill / Finish Manufacturing Market: Distribution by Company Size
26.3.1. Biologics Fill / Finish Manufacturing Market for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.2. Biologics Fill / Finish Manufacturing Market for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
26.3.3. Biologics Fill / Finish Manufacturing Market for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)

27. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN NORTH AMERICA

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Biologics Fill / Finish Manufacturing Market in North America, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.1. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Country
27.3.1.1. Biologics Fill / Finish Manufacturing Market in the US, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.1.2. Biologics Fill / Finish Manufacturing Market in Canada, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.1.3. Biologics Fill / Finish Manufacturing Market in Mexico, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.2. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Primary Packaging Container Used
27.3.2.1. Biologics Fill / Finish Manufacturing Market in North America for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.2.2. Biologics Fill / Finish Manufacturing Market in North America for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.2.3. Biologics Fill / Finish Manufacturing Market in North America for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.2.4. Biologics Fill / Finish Manufacturing Market in North America for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Biologic Manufactured
27.3.3.1. Biologics Fill / Finish Manufacturing Market in North America for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3.2. Biologics Fill / Finish Manufacturing Market in North America for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3.3. Biologics Fill / Finish Manufacturing Market in North America for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3.4. Biologics Fill / Finish Manufacturing Market in North America for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3.5. Biologics Fill / Finish Manufacturing Market in North America for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3.6. Biologics Fill / Finish Manufacturing Market in North America for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.3.7. Biologics Fill / Finish Manufacturing Market in North America for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.4. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Scale of Operation
27.3.4.1. Biologics Fill / Finish Manufacturing Market in North America for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.4.2. Biologics Fill / Finish Manufacturing Market in North America for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.5. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Therapeutic Area
27.3.5.1. Biologics Fill / Finish Manufacturing Market in North America for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.5.2. Biologics Fill / Finish Manufacturing Market in North America for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.5.3. Biologics Fill / Finish Manufacturing Market in North America for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.5.4. Biologics Fill / Finish Manufacturing Market in North America for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.5.5. Biologics Fill / Finish Manufacturing Market in North America for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.5.6. Biologics Fill / Finish Manufacturing Market in North America for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.6. Biologics Fill / Finish Manufacturing Market in North America: Distribution by End User
27.3.6.1. Biologics Fill / Finish Manufacturing Market in North America for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.6.2. Biologics Fill / Finish Manufacturing Market in North America for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.7. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Player
27.3.7.1. Biologics Fill / Finish Manufacturing Market in North America for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.7.2. Biologics Fill / Finish Manufacturing Market in North America for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.8. Biologics Fill / Finish Manufacturing Market in North America: Distribution by Company Size
27.3.8.1. Biologics Fill / Finish Manufacturing Market in North America for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.8.2. Biologics Fill / Finish Manufacturing Market in North America for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.3.8.3. Biologics Fill / Finish Manufacturing Market in North America for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation

28. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN EUROPE

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biologics Fill / Finish Manufacturing Market in Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Country
28.3.1.1. Biologics Fill / Finish Manufacturing Market in Germany, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.2. Biologics Fill / Finish Manufacturing Market in France, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.3. Biologics Fill / Finish Manufacturing Market in the UK, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.4. Biologics Fill / Finish Manufacturing Market in Switzerland, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.5. Biologics Fill / Finish Manufacturing Market in Belgium, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.6. Biologics Fill / Finish Manufacturing Market in Italy, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.7. Biologics Fill / Finish Manufacturing Market in Austria, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.8. Biologics Fill / Finish Manufacturing Market in Spain, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.9. Biologics Fill / Finish Manufacturing Market in Netherlands, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.10. Biologics Fill / Finish Manufacturing Market in Poland, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.11. Biologics Fill / Finish Manufacturing Market in Portugal, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.1.12. Biologics Fill / Finish Manufacturing Market in Rest of Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.2. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Primary Packaging Container Used
28.3.2.1. Biologics Fill / Finish Manufacturing Market in Europe for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.2.2. Biologics Fill / Finish Manufacturing Market in Europe for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.2.3. Biologics Fill / Finish Manufacturing Market in Europe for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.2.4. Biologics Fill / Finish Manufacturing Market in Europe for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Biologic Manufactured
28.3.3.1. Biologics Fill / Finish Manufacturing Market in Europe for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3.2. Biologics Fill / Finish Manufacturing Market in Europe for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3.3. Biologics Fill / Finish Manufacturing Market in Europe for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3.4. Biologics Fill / Finish Manufacturing Market in Europe for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3.5. Biologics Fill / Finish Manufacturing Market in Europe for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3.6. Biologics Fill / Finish Manufacturing Market in Europe for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.3.7. Biologics Fill / Finish Manufacturing Market in Europe for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.4. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Scale of Operation
28.3.4.1. Biologics Fill / Finish Manufacturing Market in Europe for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.4.2. Biologics Fill / Finish Manufacturing Market in Europe for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.5. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Therapeutic Area
28.3.5.1. Biologics Fill / Finish Manufacturing Market in Europe for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.5.2. Biologics Fill / Finish Manufacturing Market in Europe for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.5.3. Biologics Fill / Finish Manufacturing Market in Europe for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.5.4. Biologics Fill / Finish Manufacturing Market in Europe for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.5.5. Biologics Fill / Finish Manufacturing Market in Europe for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.5.6. Biologics Fill / Finish Manufacturing Market in Europe for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.6. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by End User
28.3.6.1. Biologics Fill / Finish Manufacturing Market in Europe for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.6.2. Biologics Fill / Finish Manufacturing Market in Europe for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.7. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Player
28.3.7.1. Biologics Fill / Finish Manufacturing Market in Europe for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.7.2. Biologics Fill / Finish Manufacturing Market in Europe for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.8. Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Company Size
28.3.8.1. Biologics Fill / Finish Manufacturing Market in Europe for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.8.2. Biologics Fill / Finish Manufacturing Market in Europe for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.3.8.3. Biologics Fill / Finish Manufacturing Market in Europe for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN ASIA-PACIFIC

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Country
29.3.1.1. Biologics Fill / Finish Manufacturing Market in China, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.2. Biologics Fill / Finish Manufacturing Market in India, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.3. Biologics Fill / Finish Manufacturing Market in South Korea, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.4. Biologics Fill / Finish Manufacturing Market in Taiwan, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.5. Biologics Fill / Finish Manufacturing Market in Japan, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.6. Biologics Fill / Finish Manufacturing Market in Singapore, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.7. Biologics Fill / Finish Manufacturing Market in Australia, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.1.8. Biologics Fill / Finish Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Type of Primary Packaging Container Used
29.3.2.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.2.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.2.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.2.4. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Type of Biologic Manufactured
29.3.3.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3.4. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3.5. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3.6. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.3.7. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.4. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
29.3.4.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.4.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.5. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
29.3.5.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.5.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.5.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.5.4. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.5.5. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.5.6. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.6. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by End User
29.3.6.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.6.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.7. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Type of Player
29.3.7.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.7.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.8. Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Company Size
29.3.8.1. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.8.2. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.3.8.3. Biologics Fill / Finish Manufacturing Market in Asia-Pacific for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN MIDDLE EAST AND NORTH AFRICA

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Country
30.3.1.1. Biologics Fill / Finish Manufacturing Market in Israel, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.1.2. Biologics Fill / Finish Manufacturing Market in Bahrain, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.1.3. Biologics Fill / Finish Manufacturing Market in Saudi Arabia, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.1.4. Biologics Fill / Finish Manufacturing Market in Iran, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Type of Primary Packaging Container Used
30.3.2.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.2.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.2.3. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.2.4. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Type of Biologic Manufactured
30.3.3.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3.3. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3.4. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3.5. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3.6. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.3.7. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.4. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
30.3.4.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.4.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.5. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
30.3.5.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.5.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.5.3. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.5.4. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.5.5. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.5.6. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.6. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by End User
30.3.6.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.6.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.7. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Type of Player
30.3.7.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.7.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.8. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Company Size
30.3.8.1. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.8.2. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.3.8.3. Biologics Fill / Finish Manufacturing Market in Middle East and North Africa for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation

31. BIOLOGICS FILL / FINISH MANUFACTURING MARKET IN LATIN AMERICA

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Biologics Fill / Finish Manufacturing Market in Latin America, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.1. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Country
31.3.1.1. Biologics Fill / Finish Manufacturing Market in South Africa, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.1.2. Biologics Fill / Finish Manufacturing Market in Argentina, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.2. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Type of Primary Packaging Container Used
31.3.2.1. Biologics Fill / Finish Manufacturing Market in Latin America for Vials, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.2.2. Biologics Fill / Finish Manufacturing Market in Latin America for Syringes, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.2.3. Biologics Fill / Finish Manufacturing Market in Latin America for Ampoules, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.2.4. Biologics Fill / Finish Manufacturing Market in Latin America for Cartridges, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Type of Biologic Manufactured
31.3.3.1. Biologics Fill / Finish Manufacturing Market in Latin America for Antibodies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3.2. Biologics Fill / Finish Manufacturing Market in Latin America for Recombinant Proteins, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3.3. Biologics Fill / Finish Manufacturing Market in Latin America for Vaccines, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3.4. Biologics Fill / Finish Manufacturing Market in Latin America for Cell Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3.5. Biologics Fill / Finish Manufacturing Market in Latin America for Gene Therapies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3.6. Biologics Fill / Finish Manufacturing Market in Latin America for Nucleic Acids / Oligonucleotides, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.3.7. Biologics Fill / Finish Manufacturing Market in Latin America for Other Biologics, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.4. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Scale of Operation
31.3.4.1. Biologics Fill / Finish Manufacturing Market in Latin America for Commercial Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.4.2. Biologics Fill / Finish Manufacturing Market in Latin America for Preclinical / Clinical Scale, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.5. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Therapeutic Area
31.3.5.1. Biologics Fill / Finish Manufacturing Market in Latin America for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.5.2. Biologics Fill / Finish Manufacturing Market in Latin America for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.5.3. Biologics Fill / Finish Manufacturing Market in Latin America for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.5.4. Biologics Fill / Finish Manufacturing Market in Latin America for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.5.5. Biologics Fill / Finish Manufacturing Market in Latin America for Autoimmune Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.5.6. Biologics Fill / Finish Manufacturing Market in Latin America for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.6. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by End User
31.3.6.1. Biologics Fill / Finish Manufacturing Market in Latin America for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.6.2. Biologics Fill / Finish Manufacturing Market in Latin America for Contract Manufacturing Organizations and Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.7. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Type of Player
31.3.7.1. Biologics Fill / Finish Manufacturing Market in Latin America for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.7.2. Biologics Fill / Finish Manufacturing Market in Latin America for Non- Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.8. Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Company Size
31.3.8.1. Biologics Fill / Finish Manufacturing Market in Latin America for Large Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.8.2. Biologics Fill / Finish Manufacturing Market in Latin America for Mid-sized Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.3.8.3. Biologics Fill / Finish Manufacturing Market in Latin America for Small Companies, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
31.4. Data Triangulation and Validation

32. BIOLOGICS FILL / FINISH MANUFACTURING MARKET, BY LEADING PLAYERSSECTION VII: CASE STUDIES

33. KEY PERFORMANCE INDICATORS FOR BIOLOGIC MANUFACTURING AND FILL / FINISH

33.1. Chapter Overview
33.2. Biologics Manufacturing and Fill / Finish: Key Performance Indicators
33.2.1. Financial Indicators
33.2.1.1. Big Pharma Perspective
33.2.1.2. Contract Manufacturers Perspective
33.2.2. Process and Capability Indicators
33.2.2.1. Big Pharma Perspective
33.2.2.2. Contract Manufacturers Perspective
33.2.3. Market Reputation Indicators
33.2.3.1. Big Pharma Perspective
33.2.3.2. Contract Manufacturers Perspective
33.2.4. Other Important Performance Indicators
33.3. Conclusion

34. CASE STUDY: ROBOTICS IN PHARMACEUTICAL PACKAGING

34.1. Chapter Overview
34.2. Role of Robotic Systems in Pharmaceutical Industry
34.3. Biologics Fill / Finish Service Providers: List of Equipment Offered
34.4. Role of Robotic Systems in Fill / Finish Operations
34.4.1. Type of Robots Used in Pharmaceutical Operations
34.4.2. Key Considerations for Selecting a Robotic System
34.4.3. Advantages of Robotic Systems in Fill / Finish Operations
34.4.4. Disadvantages of Robotic Systems in Fill / Finish Operations
34.5. Companies Providing Robots to be Used in the Pharmaceutical Industry
34.6. Companies Providing Isolator based Aseptic Filling Systems
34.7. Concluding Remarks

35. CASE STUDY: READY-TO-USE PACKAGING COMPONENTS FOR ASEPTIC FILL / FINISH

35.1. Chapter Overview
35.2. Role of Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations
35.2.1. Advantages of Ready-to-Use Packaging Components
35.2.2. Disadvantages of Ready-to-Use Packaging Components
35.3. Companies Providing Ready-to-Use Packaging Components
35.4. Concluding Remarks

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

36. INSIGHTS FROM PRIMARY RESEARCH

36.1. Chapter Overview
36.2. Large Company, US
36.2.1. Company Snapshot
36.2.2. Interview Transcript
36.3. Mid-sized Company, Netherlands
36.3.1. Company Snapshot
36.3.2. Interview Transcript
36.4. Mid-sized Company, Poland
36.4.1. Company Snapshot
36.4.2. Interview Transcript
36.5. Very Large Company, India
36.5.1. Company Snapshot
36.5.2. Interview Transcript
36.6. Mid-sized Company, US
36.6.1. Company Snapshot
36.6.2. Interview Transcript
36.7. Mid-sized Company, France
36.7.1. Company Snapshot
36.7.2. Interview Transcript
36.8. Mid-sized Company, Czech Republic
36.8.1. Company Snapshot
36.8.2. Interview Transcript
36.9. Large Company, Germany
36.9.1. Company Snapshot
36.9.2. Interview Transcript
36.10. Mid-sized Company, Netherlands
36.10.1. Company Snapshot
36.10.2. Interview Transcript

37. REPORT CONCLUSIONSECTION IX: APPENDIX38. TABULATED DATA39. LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Partnerships and Collaborations
Figure 5.3 Executive Summary: Recent Expansions
Figure 5.4 Executive Summary: Capacity Analysis
Figure 5.5 Executive Summary: Demand Analysis
Figure 5.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Types of Biologics
Figure 6.2 Commonly Outsourced Operations in Biopharmaceutical Industry
Figure 6.3 Steps Involved in Fill / Finish of Biologics
Figure 6.4 Key Considerations while Selecting a Fill / Finish Service Provider
Figure 6.5 Advantages of Outsourcing Biologics Fill / Finish Operations
Figure 7.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Figure 7.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Figure 7.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Figure 7.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 7.5 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Figure 7.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Manufactured
Figure 7.7 Biologics Fill / Finish Service Providers: Distribution by Presence of Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability
Figure 7.8 Biologics Fill / Finish Service Providers: Distribution by Type of Dosage Form
Figure 7.9 Biologics Fill / Finish Service Providers: Distribution by Type of Primary Packaging Container Used
Figure 7.10 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
Figure 8.1 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers based in North America (Peer Group I)
Figure 8.2 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers based in Europe (Peer Group II)
Figure 8.3 Company Competitiveness Analysis: Biologics Fill / Finish Service Providers based in Asia-Pacific and Rest of the World (Peer Group III)
Figure 9.1 AbbVie (Parent Company of AbbVie Contract Manufacturing): Annual Revenues, FY 2019 onwards (USD Billion)
Figure 9.2 Catalent (Parent Company of Catalent Biologics): Annual Revenues, FY 2019 onwards (USD Billion)
Figure 9.3 Lifecore Biomedical: Annual Revenues, FY 2021 onwards (USD Million)
Figure 9.4 Thermo Fisher Scientific (Parent Company of Patheon pharma services): Annual Revenues, FY 2019 onwards (USD Billion)
Figure 10.1 Boehringer Ingelheim (Parent Company of Boehringer Ingelheim BioXcellence): Annual Revenues, FY 2019 onwards (EUR Billion)
Figure 10.2 CordenPharma: Annual Revenues, FY 2021 onwards (EUR Million)
Figure 10.3 Fresenius Kabi: Annual Revenues, FY 2019 onwards (EUR Billion)
Figure 10.4 Lonza: Annual Revenues, FY 2019 onwards (CHF Billion)
Figure 10.5 Recipharm: Annual Revenues, FY 2019 onwards (EUR Million)
Figure 10.6 WACKER: Annual Revenues, FY 2019 onwards (EUR Billion)
Figure 11.1 Asymchem: Annual Revenues, FY 2019 onwards (RMB Billion)
Figure 11.2 WuXi Biologics: Annual Revenues, FY 2019 onwards (RMB Billion)
Figure 12.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2023
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Distribution by Type and Year of Partnership, Since 2023
Figure 12.4 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 12.5 Partnerships and Collaborations: Distribution by Type of Partner Company
Figure 12.6 Most Active Players: Distribution by Number of Partnerships
Figure 12.7 Partnerships and Collaborations: Distribution by Local and International Agreements
Figure 12.8 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Figure 13.1 Recent Expansions: Cumulative Year-wise Trend, Since 2019
Figure 13.2 Recent Expansions: Distribution by Type of Expansion
Figure 13.3 Recent Expansions: Distribution by Type and Year of Expansion, Since 2019
Figure 13.4 Recent Expansions: Distribution by Location of Expanded Facility
Figure 13.5 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Figure 13.6 Recent Expansions: Distribution by Area of Expanded Facility (sq. ft.)
Figure 13.7 Recent Expansions: Distribution by Scale of Operation
Figure 13.8 Recent Expansions: Distribution by Type of Primary Packaging Container Used
Figure 13.9 Recent Expansions: Distribution by Type of Expansion and Type of Primary Packaging Container Used
Figure 13.10 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 13.11 Most Active Players: Distribution by Number of Recent Expansions
Figure 15.1 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Company Size
Figure 15.2 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Location of Fill / Finish Facility
Figure 15.3 Biologics Fill / Finish Capacity for Ampoules in North America
Figure 15.4 Biologics Fill / Finish Capacity for Ampoules in Europe
Figure 15.5 Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific
Figure 15.6 Biologics Fill / Finish Capacity for Ampoules in Rest of the World
Figure 15.7 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Company Size
Figure 15.8 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Location of Fill / Finish Facility
Figure 15.9 Biologics Fill / Finish Capacity for Cartridges in North America
Figure 15.10 Biologics Fill / Finish Capacity for Cartridges in Europe
Figure 15.11 Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific
Figure 15.12 Biologics Fill / Finish Capacity for Cartridges in Rest of the World
Figure 15.13 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Company Size
Figure 15.14 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Location of Fill / Finish Facility
Figure 15.15 Biologics Fill / Finish Capacity for Syringes in North America
Figure 15.16 Biologics Fill / Finish Capacity for Syringes in Europe
Figure 15.17 Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
Figure 15.18 Biologics Fill / Finish Capacity for Syringes in Rest of the World
Figure 15.19 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Company Size
Figure 15.20 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Location of Fill / Finish Facility
Figure 15.21 Biologics Fill / Finish Capacity for Vials in North America
Figure 15.22 Biologics Fill / Finish Capacity for Vials in Europe
Figure 15.23 Biologics Fill / Finish Capacity for Vials in Asia-Pacific
Figure 15.24 Biologics Fill / Finish Capacity for Vials in Rest of the World
Figure 16.1 Global Annual Demand for Biologics Fill / Finish Manufacturing, Since 2024 (in million liters)
Figure 16.2 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Scale of Operation (in million liters)
Figure 16.3 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Type of Primary Packaging Container Used (in million liters)
Figure 16.4 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Geography (in million liters)
Figure 17.1 Regional Capability Analysis: Biologics Fill / Finish Manufacturing Capabilities in North America
Figure 17.2 Regional Capability Analysis: Biologics Fill / Finish Manufacturing Capabilities in Europe
Figure 17.3 Regional Capability Analysis: Biologics Fill / Finish Manufacturing Capabilities in Asia-Pacific and Rest of the World
Figure 19.1 Global Biologics Fill / Finish Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 19.2 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Case (USD Billion)
Figure 19.3 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Case (USD Billion)
Figure 20.1 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container Used
Figure 20.2 Biologics Fill / Finish Manufacturing Market for Vials, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.3 Biologics Fill / Finish Manufacturing Market for Syringes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.4 Biologics Fill / Finish Manufacturing Market for Ampoules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.5 Biologics Fill / Finish Manufacturing Market for Cartridges, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 20.6 Market Movement Analysis: Type of Primary Packaging Container Used
Figure 20.7 Penetration-Growth (P-G) Matrix: Type of Primary Packaging Container Used
Figure 21.1 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologics Manufactured
Figure 21.2 Biologics Fill / Finish Manufacturing Market for Antibodies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.3 Biologics Fill / Finish Manufacturing Market for Recombinant Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.4 Biologics Fill / Finish Manufacturing Market for Vaccines, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.5 Biologics Fill / Finish Manufacturing Market for Cell Therapies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.6 Biologics Fill / Finish Manufacturing Market for Gene Therapies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.7 Biologics Fill / Finish Manufacturing Market for Nucleic Acids / Oligonucleotides, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 21.8 Biologics Fill / Finish Manufacturing Market for Other Biologics, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.1 Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation
Figure 22.2 Biologics Fill / Finish Manufacturing Market for Commercial Scale, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 22.3 Biologics Fill / Finish Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.1 Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area
Figure 23.2 Biologics Fill / Finish Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.3 Biologics Fill / Finish Manufacturing Market for Cardiovascular Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.4 Biologics Fill / Finish Manufacturing Market for Metabolic Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.5 Biologics Fill / Finish Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.6 Biologics Fill / Finish Manufacturing Market for Autoimmune Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 23.7 Biologics Fill / Finish Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.1 Biologics Fill / Finish Manufacturing Market: Distribution by End User
Figure 24.2 Biologics Fill / Finish Manufacturing Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 24.3 Biologics Fill / Finish Manufacturing Market for Contract Manufacturing Organizations and Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.1 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player
Figure 25.2 Biologics Fill / Finish Manufacturing Market for Industry Players, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 25.3 Biologics Fill / Finish Manufacturing Market for Non-Industry Players, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.1 Biologics Fill / Finish Manufacturing Market: Distribution by Company Size
Figure 26.2 Biologics Fill / Finish Manufacturing Market for Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.3 Biologics Fill / Finish Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 26.4 Biologics Fill / Finish Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.1 Biologics Fill / Finish Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.2 Biologics Fill / Finish Manufacturing Market in the US, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.3 Biologics Fill / Finish Manufacturing Market in Canada, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 27.4 Biologics Fill / Finish Manufacturing Market in Mexico, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.1 Biologics Fill / Finish Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.2 Biologics Fill / Finish Manufacturing Market in Germany, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.3 Biologics Fill / Finish Manufacturing Market in France, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.4 Biologics Fill / Finish Manufacturing Market in the UK, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.5 Biologics Fill / Finish Manufacturing Market in Switzerland, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.6 Biologics Fill / Finish Manufacturing Market in Belgium, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.7 Biologics Fill / Finish Manufacturing Market in Italy, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.8 Biologics Fill / Finish Manufacturing Market in Austria, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.9 Biologics Fill / Finish Manufacturing Market in Spain, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.10 Biologics Fill / Finish Manufacturing Market in Netherlands, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.11 Biologics Fill / Finish Manufacturing Market in Poland, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.12 Biologics Fill / Finish Manufacturing Market in Portugal, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 28.13 Biologics Fill / Finish Manufacturing Market in Rest of Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.1 Biologics Fill / Finish Manufacturing Market in Asia Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.2 Biologics Fill / Finish Manufacturing Market in China, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.3 Biologics Fill / Finish Manufacturing Market in India, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.4 Biologics Fill / Finish Manufacturing Market in South Korea, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.5 Biologics Fill / Finish Manufacturing Market in Japan, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.6 Biologics Fill / Finish Manufacturing Market in Singapore, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.7 Biologics Fill / Finish Manufacturing Market in Australia, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 29.8 Biologics Fill / Finish Manufacturing Market in Rest of Asia Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.1 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.2 Biologics Fill / Finish Manufacturing Market in Israel, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.3 Biologics Fill / Finish Manufacturing Market in Bahrain, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.4 Biologics Fill / Finish Manufacturing Market in Saudi Arabia, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 30.5 Biologics Fill / Finish Manufacturing Market in Iran, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.1 Biologics Fill / Finish Manufacturing Market in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.2 Biologics Fill / Finish Manufacturing Market in South Africa, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 31.3 Biologics Fill / Finish Manufacturing Market in Argentina, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Figure 33.1 Biologics Manufacturing and Fill / Finish: Key Performance Indicators (KPIs)
Figure 33.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 33.3 Financial Indicators: Big Pharma Perspective
Figure 33.4 Financial Indicators: Contract Manufacturers Perspective
Figure 33.5 Process and Capability Indicators: Comparative Analysis of KPI of Big Pharma Companies
Figure 33.6 Process/ Capability-related Indicators: Big Pharma Perspective
Figure 33.7 Process/ Capability-related Indicators: Contract Manufacturers Perspective
Figure 33.8 Market Reputation Indicators: Comparative Analysis of KPI of Big Pharma Companies
Figure 33.9 Market Reputation-related Indicators: Big Pharma Perspective
Figure 33.10 Market Reputation-related Indicators: Contract Manufacturers Perspective
Figure 33.11 Other Important Performance Indicators: Contract Manufacturers Perspective
Figure 34.1 Key Considerations for Selecting a Robotic System
Figure 34.2 Advantages of Robotic Systems in Fill / Finish Operations
Figure 35.1 Key Drivers of Ready-to-Use Platform
Figure 37.1 Report Conclusion: Market Landscape
Figure 37.2 Report Conclusion: Partnerships and Collaborations
Figure 37.3 Report Conclusion: Recent Expansions
Figure 37.4 Report Conclusion: Capacity Analysis
Figure 37.5 Report Conclusion: Demand Analysis
Figure 37.6 Report Conclusion: Market Forecast and Opportunity Analysis (I / II)
Figure 37.7 Report Conclusion: Market Forecast and Opportunity Analysis (II / II)

LIST OF TABLES

Table 7.1 Biologics Fill / Finish Service Providers: Information on Year of Establishment, Company Size, Location of Headquarters, Number and Location of Fill / Finish Facilities
Table 7.2 Biologics Fill / Finish Service Providers: Information on Scale of Operation and Type of Biologic Manufactured
Table 7.3 Biologics Fill / Finish Service Providers: Information on Presence of Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability, Type of Dosage Form and Type of Primary Packaging Container Used
Table 7.4 Biologics Fill / Finish Service Providers: Information on Additional Services Offered
Table 9.1 Biologics Fill / Finish Service Providers in North America: List of Companies Profiled
Table 9.2 AbbVie Contract Manufacturing: Company Overview
Table 9.3 AbbVie Contract Manufacturing: Biologics Fill / Finish Service Portfolio
Table 9.4 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 9.5 Alcami: Company Overview
Table 9.6 Alcami: Biologics Fill / Finish Service Portfolio
Table 9.7 Alcami: Recent Developments and Future Outlook
Table 9.8 Catalent Biologics: Company Overview
Table 9.9 Catalent Biologics: Biologics Fill / Finish Service Portfolio
Table 9.10 Catalent Biologics: Recent Developments and Future Outlook
Table 9.11 Charles River: Company Overview
Table 9.12 Charles River: Biologics Fill / Finish Service Portfolio
Table 9.13 Curia: Company Overview
Table 9.14 Curia: Biologics Fill / Finish Service Portfolio
Table 9.15 Curia: Recent Developments and Future Outlook
Table 9.16 Grand River Aseptic Manufacturing: Company Overview
Table 9.17 Grand River Aseptic Manufacturing: Biologics Fill / Finish Service Portfolio
Table 9.18 Grand River Aseptic Manufacturing: Recent Developments and Future Outlook
Table 9.19 Lifecore Biomedical: Company Overview
Table 9.20 Lifecore Biomedical: Biologics Fill / Finish Service Portfolio
Table 9.21 Lifecore Biomedical: Recent Developments and Future Outlook
Table 9.22 Novocol Pharma: Company Overview
Table 9.23 Novocol Pharma: Biologics Fill / Finish Service Portfolio
Table 9.24 Novocol Pharma: Recent Developments and Future Outlook
Table 9.25 Patheon pharma services: Company Overview
Table 9.26 Patheon pharma services: Biologics Fill / Finish Service Portfolio
Table 9.27 Patheon pharma services: Recent Developments and Future Outlook
Table 9.28 Pharmaceutics International (Pii): Company Overview
Table 9.29 Pharmaceutics International (Pii): Biologics Fill / Finish Service Portfolio
Table 9.30 Pharmaceutics International (Pii): Recent Developments and Future Outlook
Table 10.1 Biologics Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 10.2 Boehringer Ingelheim BioXcellence: Company Overview
Table 10.3 Boehringer Ingelheim BioXcellence: Biologics Fill / Finish Service Portfolio
Table 10.4 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 10.5 Cenexi: Company Overview
Table 10.6 Cenexi: Biologics Fill / Finish Service Portfolio
Table 10.7 Cenexi: Recent Developments and Future Outlook
Table 10.8 CordenPharma: Company Overview
Table 10.9 CordenPharma: Biologics Fill / Finish Service Portfolio
Table 10.10 CordenPharma: Recent Developments and Future Outlook
Table 10.11 Element Materials Technology: Company Overview
Table 10.12 Element Materials Technology: Biologics Fill / Finish Service Portfolio
Table 10.13 Evonik: Company Overview
Table 10.14 Evonik: Biologics Fill / Finish Service Portfolio
Table 10.15 Fareva: Company Overview
Table 10.16 Fareva: Biologics Fill / Finish Service Portfolio
Table 10.17 Fresenius Kabi: Company Overview
Table 10.18 Fresenius Kabi: Biologics Fill / Finish Service Portfolio
Table 10.19 Fresenius Kabi: Recent Developments and Future Outlook
Table 10.20 GSK: Company Overview
Table 10.21 GSK: Biologics Fill / Finish Service Portfolio
Table 10.22 Lonza: Company Overview
Table 10.23 Lonza: Biologics Fill / Finish Service Portfolio
Table 10.24 Lonza: Recent Developments and Future Outlook
Table 10.25 Northway Biotechpharma: Company Overview
Table 10.26 Northway Biotechpharma: Biologics Fill / Finish Service Portfolio
Table 10.27 Northway Biotechpharma: Recent Developments and Future Outlook
Table 10.28 Rechon Life Science: Company Overview
Table 10.29 Rechon Life Science: Biologics Fill / Finish Service Portfolio
Table 10.30 Rechon Life Science: Recent Developments and Future Outlook
Table 10.31 Recipharm: Company Overview
Table 10.32 Recipharm: Biologics Fill / Finish Service Portfolio
Table 10.33 Recipharm: Recent Developments and Future Outlook
Table 10.34 WACKER: Company Overview
Table 10.35 WACKER: Biologics Fill / Finish Service Portfolio
Table 10.36 WACKER: Recent Developments and Future Outlook
Table 11.1 Biologics Fill / Finish Service Providers in Asia Pacific: List of Companies Profiled
Table 11.2 Asymchem: Company Overview
Table 11.3 Asymchem: Biologics Fill / Finish Service Portfolio
Table 11.4 Asymchem: Recent Developments and Future Outlook
Table 11.5 Bushu Pharmaceuticals: Company Overview
Table 11.6 Bushu Pharmaceuticals: Biologics Fill / Finish Service Portfolio
Table 11.7 Bushu Pharmaceuticals: Recent Developments and Future Outlook
Table 11.8 Hetero: Company Overview
Table 11.9 Hetero: Biologics Fill / Finish Service Portfolio
Table 11.10 Syngene: Company Overview
Table 11.11 Syngene: Biologics Fill / Finish Service Portfolio
Table 11.12 WuXi Biologics: Company Overview
Table 11.13 WuXi Biologics: Biologics Fill / Finish Service Portfolio
Table 11.14 WuXi Biologics: Recent Developments and Future Outlook
Table 12.1 Biologics Fill / Finish Service Providers: List of Partnerships and Collaborations, Since 2023
Table 12.2 Partnerships and Collaborations: Information on Scale of Operation and Type of Agreement
Table 13.1 Biologics Fill / Finish Service Providers: List of Recent Expansions, Since 2019
Table 15.1 Biologics Fill / Finish Service Providers: Information on Total Installed Capacity for Ampoules (Sample Data Set)
Table 15.2 Biologics Fill / Finish Service Providers: Average Capacity per Facility for Ampoules, by Company Size (Sample Dataset)
Table 15.3 Global Installed Biologics Fill / Finish Capacity for Ampoules, by Company Size (in terms of units / batch)
Table 15.4 Biologics Fill / Finish Service Providers: Information on Total Installed Capacity for Cartridges (Sample Data Set)
Table 15.5 Biologics Fill / Finish Service Providers: Average Capacity per Facility for Cartridges by Company Size (Sample Dataset)
Table 15.6 Global Installed Biologics Fill / Finish Capacity for Cartridges, by Company Size (in terms of units / batch)
Table 15.7 Biologics Fill / Finish Service Providers: Information on Total Installed Capacity for Syringes (Sample Data Set)
Table 15.8 Biologics Fill / Finish Service Providers: Average Capacity per Facility for Syringes by Company Size (Sample Dataset)
Table 15.9 Global Installed Biologics Fill / Finish Capacity for Syringes, by Company Size (in terms of units / batch)
Table 15.10 Biologics Fill / Finish Service Providers: Information on Total Installed Capacity for Vials (Sample Data Set)
Table 15.11 Biologics Fill / Finish Service Providers: Average Capacity per Facility for Vials by Company Size (Sample Dataset)
Table 15.12 Global Installed Biologics Fill / Finish Capacity for Vials, by Company Size (in terms of units / batch)
Table 27.1 Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Primary Packaging Container Used
Table 27.2 Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Biologic Manufactured
Table 27.3 Biologics Fill / Finish Manufacturing Market in North America: Distribution by Scale of Operation
Table 27.4 Biologics Fill / Finish Manufacturing Market in North America: Distribution by Therapeutic Area
Table 27.5 Biologics Fill / Finish Manufacturing Market in North America: Distribution by End User
Table 27.6 Biologics Fill / Finish Manufacturing Market in North America: Distribution by Type of Player
Table 27.7 Biologics Fill / Finish Manufacturing Market in North America: Distribution by Company Size
Table 28.1 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Primary Packaging Container Used
Table 28.2 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Biologic Manufactured
Table 28.3 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Scale of Operation
Table 28.4 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Therapeutic Area
Table 28.5 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by End User
Table 28.6 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Type of Player
Table 28.7 Biologics Fill / Finish Manufacturing Market in Europe: Distribution by Company Size
Table 29.1 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Type of Primary Packaging Container Used
Table 29.2 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Type of Biologic Manufactured
Table 29.3 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Scale of Operation
Table 29.4 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Therapeutic Area
Table 29.5 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by End User
Table 29.6 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Type of Player
Table 29.7 Biologics Fill / Finish Manufacturing Market in Asia-Pacific: Distribution by Company Size
Table 30.1 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Type of Primary Packaging Container Used
Table 30.2 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Type of Biologic Manufactured
Table 30.3 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Scale of Operation
Table 30.4 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Therapeutic Area
Table 30.5 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by End User
Table 30.6 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Type of Player
Table 30.7 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa: Distribution by Company Size
Table 31.1 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Type of Primary Packaging Container Used
Table 31.2 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Type of Biologic Manufactured
Table 31.3 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Scale of Operation
Table 31.4 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Therapeutic Area
Table 31.5 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by End User
Table 31.6 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Type of Player
Table 31.7 Biologics Fill / Finish Manufacturing Market in Latin America: Distribution by Company Size
Table 34.1 Biologics Fill / Finish Service Providers: Information on Fill / Finish Equipment Used
Table 34.2 List of Pharmaceutical Robotics Manufacturers
Table 34.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Containers
Table 35.1 List of Companies Supplying Ready-to-Use Packaging Components
Table 38.1 Biologics Fill / Finish Service Providers: Distribution by Year of Establishment
Table 38.2 Biologics Fill / Finish Service Providers: Distribution by Company Size
Table 38.3 Biologics Fill / Finish Service Providers: Distribution by Location of Headquarters
Table 38.4 Biologics Fill / Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Table 38.5 Biologics Fill / Finish Service Providers: Distribution by Scale of Operation
Table 38.6 Biologics Fill / Finish Service Providers: Distribution by Type of Biologic Manufactured
Table 38.7 Biologics Fill / Finish Service Providers: Distribution by Presence of Cytostatic or Cytotoxic or Highly Potent Substance Filling Capability
Table 38.8 Biologics Fill / Finish Service Providers: Distribution by Type of Dosage Form
Table 38.9 Biologics Fill / Finish Service Providers: Distribution by Type of Primary Packaging Container Used
Table 38.10 Biologics Fill / Finish Service Providers: Distribution by Additional Services Offered
Table 38.11 AbbVie (Parent Company of AbbVie Contract Manufacturing): Annual Revenues, FY 2019 onwards (USD Billion)
Table 38.12 Catalent (Parent Company of Catalent Biologics): Annual Revenues, FY 2019 onwards (USD Billion)
Table 38.13 Lifecore Biomedical: Annual Revenues, FY 2021 onwards (USD Million)
Table 38.14 Thermo Fisher Scientific (Parent Company of Patheon pharma services): Annual Revenues, FY 2019 onwards (USD Billion)
Table 38.15 Boehringer Ingelheim (Parent Company of Boehringer Ingelheim BioXcellence): Annual Revenues, FY 2019 onwards (EUR Billion)
Table 38.16 CordenPharma: Annual Revenues, FY 2021 onwards (EUR Million)
Table 38.17 Fresenius Kabi: Annual Revenues, FY 2019 onwards (EUR Billion)
Table 38.18 Lonza: Annual Revenues, FY 2019 onwards (CHF Billion)
Table 38.19 Recipharm: Annual Revenues, FY 2019 onwards (EUR Million)
Table 38.20 WACKER: Annual Revenues, FY 2019 onwards (EUR Billion)
Table 38.21 Asymchem: Annual Revenues, FY 2019 onwards (RMB Billion)
Table 38.22 WuXi Biologics: Annual Revenues, FY 2019 onwards (RMB Billion)
Table 38.23 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2023
Table 38.24 Partnerships and Collaborations: Distribution by Type of Partnership
Table 38.25 Partnerships and Collaborations: Distribution by Type and Year of Partnership, Since 2023
Table 38.26 Partnerships and Collaborations: Distribution by Scale of Operation
Table 38.27 Partnerships and Collaborations: Distribution by Type of Partner Company
Table 38.28 Most Active Players: Distribution by Number of Partnerships
Table 38.29 Partnerships and Collaborations: Distribution by Local and International Agreements
Table 38.30 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
Table 38.31 Recent Expansions: Cumulative Year-wise Trend, Since 2019
Table 38.32 Recent Expansions: Distribution by Type of Expansion
Table 38.33 Recent Expansions: Distribution by Type and Year of Expansion, Since 2019
Table 38.34 Recent Expansions: Distribution by Location of Expanded Facility
Table 38.35 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 38.36 Recent Expansions: Distribution by Area of Expanded Facility (sq. ft.)
Table 38.37 Recent Expansions: Distribution by Scale of Operation
Table 38.38 Recent Expansions: Distribution by Type of Primary Packaging Container Used
Table 38.39 Recent Expansions: Distribution by Type of Expansion and Type of Primary Packaging Container Used
Table 38.40 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 38.41 Most Active Players: Distribution by Number of Recent Expansions
Table 38.42 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Company Size
Table 38.43 Global Installed Biologics Fill / Finish Capacity for Ampoules: Distribution by Location of Fill / Finish Facility
Table 38.44 Biologics Fill / Finish Capacity for Ampoules in North America
Table 38.45 Biologics Fill / Finish Capacity for Ampoules in Europe
Table 38.46 Biologics Fill / Finish Capacity for Ampoules in Asia-Pacific
Table 38.47 Biologics Fill / Finish Capacity for Ampoules in Rest of the World
Table 38.48 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Company Size
Table 38.49 Global Installed Biologics Fill / Finish Capacity for Cartridges: Distribution by Location of Fill / Finish Facility
Table 38.50 Biologics Fill / Finish Capacity for Cartridges in North America
Table 38.51 Biologics Fill / Finish Capacity for Cartridges in Europe
Table 38.52 Biologics Fill / Finish Capacity for Cartridges in Asia-Pacific
Table 38.53 Biologics Fill / Finish Capacity for Cartridges in Rest of the World
Table 38.54 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Company Size
Table 38.55 Global Installed Biologics Fill / Finish Capacity for Syringes: Distribution by Location of Fill / Finish Facility
Table 38.56 Biologics Fill / Finish Capacity for Syringes in North America
Table 38.57 Biologics Fill / Finish Capacity for Syringes in Europe
Table 38.58 Biologics Fill / Finish Capacity for Syringes in Asia-Pacific
Table 38.59 Biologics Fill / Finish Capacity for Syringes in Rest of the World
Table 38.60 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Company Size
Table 38.61 Global Installed Biologics Fill / Finish Capacity for Vials: Distribution by Location of Fill / Finish Facility
Table 38.62 Biologics Fill / Finish Capacity for Vials in North America
Table 38.63 Biologics Fill / Finish Capacity for Vials in Europe
Table 38.64 Biologics Fill / Finish Capacity for Vials in Asia-Pacific
Table 38.65 Biologics Fill / Finish Capacity for Vials in Rest of the World
Table 38.66 Global Annual Demand for Biologics Fill / Finish Manufacturing, Since 2025 (in million liters)
Table 38.67 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Scale of Operation (in million liters)
Table 38.68 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Type of Primary Packaging Container Used (in million liters)
Table 38.69 Global Demand for Biologics Fill / Finish Manufacturing: Distribution by Geography (in million liters)
Table 38.70 Global Biologics Fill / Finish Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035) (USD Billion)
Table 38.71 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (Till 2035): Conservative Case (USD Billion)
Table 38.72 Global Biologics Fill / Finish Manufacturing Market, Forecasted Estimates (Till 2035): Optimistic Case (USD Billion)
Table 38.73 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Primary Packaging Container Used
Table 38.74 Biologics Fill / Finish Manufacturing Market for Vials, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.75 Biologics Fill / Finish Manufacturing Market for Syringes, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.76 Biologics Fill / Finish Manufacturing Market for Ampoules, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.77 Biologics Fill / Finish Manufacturing Market for Cartridges, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.78 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Biologics Manufactured
Table 38.79 Biologics Fill / Finish Manufacturing Market for Antibodies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.80 Biologics Fill / Finish Manufacturing Market for Recombinant Proteins, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.81 Biologics Fill / Finish Manufacturing Market for Vaccines, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.82 Biologics Fill / Finish Manufacturing Market for Cell Therapies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.83 Biologics Fill / Finish Manufacturing Market for Gene Therapies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.84 Biologics Fill / Finish Manufacturing Market for Nucleic Acids / Oligonucleotides, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.85 Biologics Fill / Finish Manufacturing Market for Other Biologics, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.86 Biologics Fill / Finish Manufacturing Market: Distribution by Scale of Operation
Table 38.87 Biologics Fill / Finish Manufacturing Market for Commercial Scale, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.88 Biologics Fill / Finish Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.89 Biologics Fill / Finish Manufacturing Market: Distribution by Therapeutic Area
Table 38.90 Biologics Fill / Finish Manufacturing Market for Oncological Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.91 Biologics Fill / Finish Manufacturing Market for Cardiovascular Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.92 Biologics Fill / Finish Manufacturing Market for Metabolic Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.93 Biologics Fill / Finish Manufacturing Market for Infectious Diseases, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.94 Biologics Fill / Finish Manufacturing Market for Autoimmune Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.95 Biologics Fill / Finish Manufacturing Market for Other Disorders, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.96 Biologics Fill / Finish Manufacturing Market: Distribution by End User
Table 38.97 Biologics Fill / Finish Manufacturing Market for Pharmaceutical / Biopharmaceutical Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.98 Biologics Fill / Finish Manufacturing Market for Contract Manufacturing Organizations and Others, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.99 Biologics Fill / Finish Manufacturing Market: Distribution by Type of Player
Table 38.100 Biologics Fill / Finish Manufacturing Market for Industry Players, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.101 Biologics Fill / Finish Manufacturing Market for Non-Industry Players, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.102 Biologics Fill / Finish Manufacturing Market: Distribution by Company Size
Table 38.103 Biologics Fill / Finish Manufacturing Market for Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.104 Biologics Fill / Finish Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.105 Biologics Fill / Finish Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.106 Biologics Fill / Finish Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.107 Biologics Fill / Finish Manufacturing Market in the US, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.108 Biologics Fill / Finish Manufacturing Market in Canada, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.109 Biologics Fill / Finish Manufacturing Market in Mexico, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.110 Biologics Fill / Finish Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.111 Biologics Fill / Finish Manufacturing Market in Germany, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.112 Biologics Fill / Finish Manufacturing Market in France, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.113 Biologics Fill / Finish Manufacturing Market in the UK, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.114 Biologics Fill / Finish Manufacturing Market in Switzerland, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.115 Biologics Fill / Finish Manufacturing Market in Belgium, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.116 Biologics Fill / Finish Manufacturing Market in Italy, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.117 Biologics Fill / Finish Manufacturing Market in Austria, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.118 Biologics Fill / Finish Manufacturing Market in Spain, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.119 Biologics Fill / Finish Manufacturing Market in Netherlands, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.120 Biologics Fill / Finish Manufacturing Market in Poland, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.121 Biologics Fill / Finish Manufacturing Market in Portugal, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.122 Biologics Fill / Finish Manufacturing Market in Rest of Europe, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.123 Biologics Fill / Finish Manufacturing Market in Asia Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.124 Biologics Fill / Finish Manufacturing Market in China, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.125 Biologics Fill / Finish Manufacturing Market in India, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.126 Biologics Fill / Finish Manufacturing Market in South Korea, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.127 Biologics Fill / Finish Manufacturing Market in Japan, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.128 Biologics Fill / Finish Manufacturing Market in Singapore, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.129 Biologics Fill / Finish Manufacturing Market in Australia, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.130 Biologics Fill / Finish Manufacturing Market in Rest of Asia Pacific, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.131 Biologics Fill / Finish Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.132 Biologics Fill / Finish Manufacturing Market in Israel, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.133 Biologics Fill / Finish Manufacturing Market in Bahrain, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.134 Biologics Fill / Finish Manufacturing Market in Saudi Arabia, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.135 Biologics Fill / Finish Manufacturing Market in Iran, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.136 Biologics Fill / Finish Manufacturing Market in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.137 Biologics Fill / Finish Manufacturing Market in South Africa, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)
Table 38.138 Biologics Fill / Finish Manufacturing Market in Argentina, Historical Trends (Since 2018) and Forecasted Estimates (Till 2035): Conservative, Base and Optimistic Scenario (USD Billion)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AbbVie Contract Manufacturing
Asymchem
Boehringer Ingelheim BioXcellence
Catalent Biologics
Charles River
Evonik
Fareva
Fresenius Kabi
GSK
Hetero
Lonza
Patheon Pharma Services
Pierre Fabre
Recipharm
Sandoz
Syngene
WACKER
WuXi Biologics

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4270EUR$4,799USD£3,759GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6228EUR$6,999USD£5,482GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€16017EUR$17,999USD£14,099GBP